Precipio, Inc.
PRPOPrecipio, Inc. in brief
Precipio, Inc. is a listed company in the Diagnostics and Research industry, based in New Haven, Connecticut, USA. Its market value was $38 M on 22 October 2026, which makes it the 22,200th largest listed company in the world and the 3,967th largest in the USA on this site. In the year to December 2025 it had sales of $53 M and a net loss of $0 M. Ilan Danieli is its chief executive. Its largest product and service lines by sales in 2025 were Service revenue, net (95%). Its shares trade under the symbol PRPO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Precipio, Inc.
We are a healthcare biotechnology company with a mission to battle the systemic problem of disease misdiagnosis, by focusing on improving cancer diagnostics, particularly, hematologic malignancies. Our objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. We aim to achieve this through a combination of clinical laboratory services and proprietary diagnostic product development. By integrating diagnostic services with product development, our service business doubles as a self-funded research and development unit, enabling us to achieve rapid and cost-efficient innovation rather than being a major cost center for us.
From the company's annual report filed with the US SEC: read the report
Precipio, Inc. timeline
- 2000
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- ✎Renamed Precipio, Inc.Formerly Transgenomic Inc.
- 2025
- 💰Record revenue of $53 millionFY2025, the highest of the 8 years on record.
Events of Precipio, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,559 (Jan 2020) · #4,207 (Jan 2021) · #5,071 (Jan 2022) · #5,472 (Dec 2022) · #5,458 (Jul 2023) · #4,534 (Jan 2024) · #2,153 (Mar 2026) · #3,790 (Aug 2026) · #3,912 (Oct 2026) · #3,970 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.6×
- Price / book
- 2.6×
- Free cash flow yield
- 0.9%
- Net margin (TTM)
- -1.8%
- Operating margin
- -2.2%
- Return on equity
- -7.8%
- Liabilities / assets
- 31.7%
- Net debt
- $-3M
- Revenue growth
- +28.0%
- R&D / revenue
- 3.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $53M | +28.0% | $-1M | $-0M | -0.7% |
| Dec 2024 | $42M | +41.6% | $-4M | $-4M | -10.3% |
| Dec 2023 | $30M | +45.4% | $-8M | $-6M | -19.8% |
| Dec 2022 | $20M | +14.8% | $-13M | $-12M | -60.0% |
| Dec 2021 | $18M | +11.3% | $-10M | $-9M | -48.2% |
| Dec 2020 | $16M | +94.1% | $-9M | $-11M | -66.8% |
| Dec 2019 | $8M | +66.9% | $-11M | $-13M | -161.9% |
| Dec 2018 | $5M | — | $-14M | $-16M | -320.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $1M | $0M | $0M | $-0.23 | — |
| Dec 2024 | $0M | $0M | $0M | $-2.93 | — |
| Dec 2023 | $-4M | $0M | $-4M | $-4.51 | — |
| Dec 2022 | $-8M | $0M | $-8M | $-10.73 | — |
| Dec 2021 | $-7M | $1M | $-7M | $-0.40 | — |
| Dec 2020 | $-7M | $0M | $-8M | $-0.85 | — |
| Dec 2019 | $-9M | $0M | $-9M | $-2.33 | — |
| Dec 2018 | $-7M | $0M | $-7M | $-13.82 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $16M (+8.2% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 29, 20268-KCurrent reportRegulation FD disclosure
- Aug 14, 20268-KCurrent reportResults of operations
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Jul 31, 20268-KCurrent reportRegulation FD disclosure
- Jun 15, 20268-KCurrent reportShareholder vote
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 6, 20268-KCurrent reportRegulation FD disclosure
- Apr 28, 2026DEF 14AProxy statement
- Mar 30, 202610-KAnnual report · period to Dec 2025
- Feb 27, 20268-KCurrent reportResults of operations
Official filings of Precipio, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $53 M
- Operating income
- $-1 M
- Net income
- $-0 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $21 M
- Total liabilities
- $7 M
- Total equity
- $15 M
As of December-2025
Top 20 institutional investors in Precipio, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Two Sigma Investments, LP | 77,040 | New | 4.30% | $2 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 57,439 | +11,291 (+24.47%) | 3.20% | $1 M | Nov 13, 2026 |
| 3 | BlackRock, Inc. | 34,410 | -245 (-0.71%) | 1.92% | $1 M | Nov 13, 2026 |
| 4 | Jane Street Group, LLC | 32,465 | New | 1.81% | $1 M | Nov 12, 2026 |
| 5 | Geode Capital Management, LLC | 17,180 | -1,511 (-8.08%) | 0.96% | $0 M | Nov 6, 2026 |
| 6 | XTX Topco Ltd | 15,710 | +6,260 (+66.24%) | 0.88% | $0 M | Nov 16, 2026 |
| 7 | Trexquant Investment LP | 11,848 | New | 0.66% | $0 M | Nov 16, 2026 |
| 8 | UBS Group AG | 9,929 | +9,586 (+2794.75%) | 0.55% | $0 M | Nov 10, 2026 |
| 9 | Vanguard Fiduciary Trust Co | 9,407 | 0 (0.00%) | 0.52% | $0 M | Nov 13, 2026 |
| 10 | HRT Financial LP | 8,779 | New | 0.49% | $0 M | Nov 13, 2026 |
| 11 | BNP Paribas Financial Markets | 2,464 | New | 0.14% | $0 M | Nov 12, 2026 |
| 12 | Vanguard Global Advisers, LLC | 1,098 | New | 0.06% | $0 M | Nov 13, 2026 |
| 13 | Morgan Stanley | 407 | +400 (+5714.29%) | 0.02% | $0 M | Nov 13, 2026 |
| 14 | Royal Bank Of Canada | 64 | +53 (+481.82%) | 0.00% | $0 M | Nov 16, 2026 |
| 15 | Wells Fargo & Company/mn | 50 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 16 | Tower Research Capital LLC (TRC) | 28 | -4 (-12.50%) | 0.00% | $0 M | Nov 16, 2026 |
| 17 | Caitong International Asset Management Co., Ltd | 4 | +3 (+300.00%) | 0.00% | $0 M | Oct 29, 2026 |
| 18 | Allworth Financial LP | 3 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 19 | IFP Advisors, Inc | 3 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 20 | FMR LLC | 2 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Precipio, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 28,367 | $1 M | 1.6% | <0.01% | +206% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 17,695 | $0 M | 0.99% | <0.01% | +9.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 8,035 | $0 M | 0.45% | <0.01% | +6.4% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 5,388 | $0 M | 0.30% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 3,188 | $0 M | 0.18% | <0.01% | +71% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 3,097 | $0 M | 0.17% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 2,616 | $0 M | 0.15% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 2,272 | $0 M | 0.13% | <0.01% | +16% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 1,244 | $0 M | 0.07% | <0.01% | +100% | Jul 31, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 1,008 | $0 M | 0.06% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 614 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 479 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 456 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 410 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 355 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 114 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 100 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 86 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 18 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Precipio, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David Seth CohenDirector | Grant or award | +582 | $22.54 | $13 K | 55,781 | Form 4 |
| filed | Christina Rizopoulos ValauriDirector | Grant or award | +122 | $22.54 | $3 K | 5,750 | Form 4 |
| filed | David Seth CohenDirector | Grant or award | +520 | $25.24 | $13 K | 55,199 | Form 4 |
| filed | Christina Rizopoulos ValauriDirector | Grant or award | +108 | $25.24 | $3 K | 5,628 | Form 4 |
| filed | Jeffrey CossmanDirector | Grant or award | +416 | $25.24 | $10 K | 16,549 | Form 4 |
| filed | Richard A. SandbergDirector | Sellindirect | -900 | $25.02 | $23 K | 3,000 | Form 4 |
| filed | Richard A. SandbergDirector | Sellindirect | -500 | $25.00 | $13 K | 3,900 | Form 4 |
| filed | Richard A. SandbergDirector | Sell | -2,034 | $24.89 | $51 K | 8,142 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Precipio, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-20 reverse split ; 15-for-1 split ; 1-for-30.3 reverse split in the period to ; 1-for-12 reverse split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2026 | Q3 2026 | $0M |
Trading halts
- 2025-04-23 19:04 UTC, code LUDP, resumed 19:14 UTC
Fails to deliver
- : 208 shares at $21.25
- : 2,381 shares at $21.72
- : 1,527 shares at $21.89
- : 1,342 shares at $21.38
- : 2,533 shares at $23.19
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Precipio, Inc. scorecard#
Passes 12 of the 22 checks that could be worked out: strongest in growth (5 of 6), weakest in valuation (2 of 5). Fiscal year 2025; market cap of Oct 22, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.6×Price to book 2.6× against Diagnostics and Research's median of 3.7×.
- ✓Price to sales below its peers' median0.6×Price to sales 0.6× against Diagnostics and Research's median of 4.5×.
- ✗Free cash flow yield above 5%0.9%Free cash flow is 0.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth5 of 6
- ✓Revenue grew in the newest year28.0%Revenue up 28.0% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years38.1%38.1% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median38.1%38.1% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-0.23 vs -2.93Diluted EPS -0.23 in fiscal 2025 against -2.93 the year before (report's currency).
- ✓Net income higher than five years earlier-$0 M-$0 M in fiscal 2025 against -$11 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability2 of 5
- ✗Profitable in the newest year-$0 MNet income -$0 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-2.2%-2.2% against Diagnostics and Research's median of -2.4% (66 companies).
- ✗Return on equity above 15%-2.7%-2.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-2.2%-2.2% in fiscal 2025 against -63.1% in 2022.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities1.6×Current ratio 1.61 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.01 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $3 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-0.92Z-score -0.92 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year9.5%Diluted shares up 9.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Precipio, Inc.'s statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -2.2% | -2.4% | |
| Net margin | -0.7% | -3.6% | |
| Return on equity | -2.7% | -5.4% | |
| Revenue growth, 3 years a year | 38.1% | 3.6% | |
| Revenue growth | 28.0% | 6.6% | |
| Debt to equity | 0.01× | 0.57× |
7of 9on the Piotroski tests of financial strength
- Net loss of $0 million, the 17th loss-making year in a row.
- The share count rose 9.5% in the year.
- Receivables grew 147% while revenue grew 28%: customers are paying later, or sales were booked ahead of cash.
- Revenue has grown 9 years in a row.
Precipio, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 53+28.0%100% | 42+41.6%100% | 30+45.4%100% | 20+14.7%100% | 18+11.3%100% | 16+94.3%100% | 8.2+66.8%100% | 4.9+69.2%100% | 2.9r1.7+68.1%100% | 1.7r1.6—100% | |
| Cost of revenue | 13+21.6%24.9% | 11+19.5%26.3% | 9.2+33.0%31.1% | 6.9+6.9%34.0% | 6.5+30.7%36.5% | 4.9+69.9%31.1% | 2.9+10.2%35.6% | 2.6+84.4%53.8% | 1.4+47.5%49.4% | 1.0r1.8—56.3% | |
| Gross profit | 11+41.6%20.0% | 7.6+25.6%18.1% | 6.0+140%20.4% | 2.5+4.9%12.4% | 2.4+108%13.5% | 1.2+425%7.2% | 0.2−2.7%2.7% | 0.2−22.9%4.6% | 0.3−61.2%10.1% | 0.8r−0.2—43.7% | |
| Research and development | 1.6+23.1%3.0% | 1.3−23.5%3.1% | 1.70.0%5.8% | 1.7+30.8%8.4% | 1.3+8.3%7.4% | 1.20.0%7.6% | 1.2+9.1%14.7% | 1.1+120%22.4% | 0.5—17.3% | 0r1.4—0.0% | |
| Selling, general and administrative | — | — | — | — | — | 10+7.0%64.8% | 9.6+1.8%118% | 9.5+45.7%193% | 6.5+163%224% | 2.5r6.2—143% | |
| Operating expenses | 12+1.1%22.3% | 12−13.7%28.2% | 14−10.9%46.2% | 15+27.5%75.4% | 12+16.6%67.9% | 10−8.2%64.8% | 11−20.7%137% | 14−10.5%288% | 16+541%546% | 2.5r7.6—143% | |
| Operating income | −1.2—−2.2% | −4.2—−10.1% | −7.6—−25.8% | −13—−63.1% | −9.6—−54.4% | −9.1—−57.6% | −11—−134% | −14—−284% | −16—−536% | −1.7r−7.8—−99.4% | |
| Other non-operating income (expense) | 0.8—1.6% | −0.1—−0.2% | — | — | — | — | — | — | — | 0.0r−0.0—0.2% | |
| Income before tax | −0.4—−0.7% | −4.3—−10.3% | −5.9—−19.8% | −12—−60.0% | −8.5—−48.2% | −11—−66.7% | −13—−163% | −16—−326% | −21—−715% | −2.2r−8.3—−129% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | −0.1—−0.9% | −0.3−180%−5.7% | 0.3—12.1% | 0—0.0% | |
| Income from continuing operations | — | — | — | — | −8.5—−48.2% | −11—−66.7% | −13—−162% | −16—−320% | −21—−715% | −2.2r−8.3—−129% | |
| Income from discontinued operations | — | — | — | — | — | — | — | — | — | 0.7—37.9% | |
| Net income including minority interests | −0.4—−0.7% | −4.3—−10.3% | −5.9—−19.8% | −12—−60.0% | −8.5—−48.2% | −11—−66.7% | −13—−162% | — | — | — | |
| Minority interests' share of net income | — | — | — | 0.0+92.3%0.1% | 0.0−51.9%0.1% | 0.0—0.2% | — | — | — | — | |
| Net income attributable to shareholders | −0.4—−0.7% | −4.3—−10.3% | — | — | — | — | −13—−162% | −16—−320% | −21—−715% | −2.2r−7.6—−129% | |
| Earnings per share, basic | -0.23—— | -2.93—— | -4.51—— | -10.73r-0.54—— | -0.40—— | -0.85—— | -2.33—— | -13.82r-0.92—— | -7.16—— | -9.44r-0.35—— | |
| Earnings per share, diluted | -0.23—— | -2.93—— | -4.51—— | -10.73r-0.54—— | -0.40—— | -0.85—— | -2.33—— | -13.82r-0.92—— | -7.16—— | -9.44r-0.35—— | |
| Shares, weighted average (basic) | 1.6+9.5%— | 1.5+12.9%— | 1.3+14.1%— | 1.1r23−94.6%— | 21+28.0%— | 16—— | — | — | — | — | |
| Shares, weighted average (diluted) | 1.6+9.5%— | 1.5+12.9%— | 1.3+14.1%— | 1.1r23−94.6%— | 21+28.0%— | 16+189%— | 5.7+295%— | 1.4r22−68.9%— | 4.6+972%— | 0.4r23—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 2.7+90.9%12.4% | 1.4−7.5%8.2% | 1.5−56.4%8.3% | 3.4−70.5%16.0% | 12+339%38.3% | 2.7+213%12.8% | 0.8+123%4.3% | 0.4−9.5%1.8% | 0.4+725%1.5% | 0.1r0.1—6.1% | |
| Receivables | 2.0+148%9.3% | 0.8−38.6%4.7% | 1.3+25.6%7.2% | 1.0+48.6%4.8% | 0.7−20.3%2.3% | 0.9+52.3%4.2% | 0.6−16.8%2.9% | 0.7−5.5%3.2% | 0.7+88.1%2.7% | 0.4r0.2—46.1% | |
| Inventory | 0.9+29.1%4.4% | 0.7+88.5%4.3% | 0.4−45.8%2.1% | 0.7+25.5%3.3% | 0.6+61.1%1.9% | 0.4+90.2%1.7% | 0.2−6.6%0.9% | 0.2+22.4%0.9% | 0.2+61.0%0.6% | 0.1r0.0—11.9% | |
| Other current assets | 0.5−13.0%2.2% | 0.5+8.9%3.2% | 0.5−5.0%2.7% | 0.5−5.1%2.4% | 0.5+69.4%1.8% | 0.3+19.1%1.6% | 0.3−48.2%1.4% | 0.5+22.1%2.4% | 0.4+3208%1.6% | 0.0r0.1—1.5% | |
| Current assets | 6.0+75.0%28.3% | 3.5−6.3%20.3% | 3.7−35.5%20.3% | 5.7−57.6%26.6% | 13+221%44.3% | 4.2+124%20.3% | 1.9+4.7%9.6% | 1.8+2.9%8.3% | 1.7+216%6.4% | 0.6r0.5—65.6% | |
| Property, plant and equipment | 0.7+1.4%3.4% | 0.7−2.7%4.2% | 0.7−15.7%4.1% | 0.9+4.9%4.1% | 0.8+202%2.7% | 0.3r0.5−35.7%1.3% | 0.4−13.1%2.2% | 0.5+40.5%2.3% | 0.4+26.1%1.3% | 0.3r0.1—33.3% | |
| Right-of-use (leased) assets | 2.6+549%12.0% | 0.4−35.5%2.3% | 0.6−19.8%3.4% | 0.8−11.1%3.5% | 0.9+180%2.8% | 0.3r0.3−41.0%1.5% | 0.5—2.7% | — | — | — | |
| Goodwill | — | — | — | — | — | — | — | — | 4.7—17.2% | — | |
| Other intangible assets | 11−8.0%51.2% | 12−7.4%69.8% | 13−6.9%70.8% | 14−6.4%64.0% | 15−6.1%48.3% | 16−5.9%75.6% | 17−13.6%85.4% | 19−5.7%89.3% | 20—75.0% | 0r0.6—0.0% | |
| Total assets | 21+25.4%100% | 17−6.1%100% | 18−15.8%100% | 22−29.4%100% | 30+47.0%100% | 21+6.2%100% | 20−9.7%100% | 22−20.7%100% | 27+3138%100% | 0.8r1.3—100% | |
| Accounts payable | 1.1+83.0%5.3% | 0.6−0.6%3.6% | 0.6−69.5%3.4% | 2.0+9.6%9.5% | 1.9+10.0%6.1% | 1.7−12.6%8.2% | 1.9−62.5%9.9% | 5.2+1.3%23.9% | 5.1+371%18.7% | 1.1r6.5—129% | |
| Debt due within a year | 0.0−89.9%0.1% | 0.3+26.4%1.7% | 0.2−7.8%1.3% | 0.3+881%1.2% | 0.0−96.0%0.1% | 0.6+102%3.1% | 0.3+22.1%1.6% | 0.3−55.2%1.2% | 0.6+48.6%2.2% | 0.4r7.8—46.9% | |
| Current liabilities | 3.8−12.2%17.6% | 4.3+36.0%25.1% | 3.1−28.0%17.4% | 4.4+3.5%20.3% | 4.2−9.5%13.8% | 4.7+7.4%22.5% | 4.3−68.5%22.2% | 14+37.2%63.7% | 10+233%36.8% | 3.0r20—358% | |
| Long-term debt | 0.0−39.0%0.2% | 0.1−27.4%0.5% | 0.1−20.9%0.6% | 0.1−16.2%0.6% | 0.2−55.8%0.5% | 0.4+82.8%1.7% | 0.2−21.7%1.0% | 0.3−91.1%1.2% | 2.8−31.5%10.4% | 4.1r0—490% | |
| Lease liabilities (non-current) | 2.2+971%10.3% | 0.2−49.4%1.2% | 0.4−29.1%2.2% | 0.6−17.6%2.7% | 0.7+658%2.3% | 0.1−71.0%0.4% | 0.3—1.6% | — | — | — | |
| Total liabilities | 6.8+37.8%31.7% | 4.9+33.5%28.8% | 3.7−28.5%20.3% | 5.1−12.0%23.9% | 5.8−10.9%19.2% | 6.6+3.9%31.6% | 6.3−59.3%32.3% | 15+8.8%71.7% | 14+94.9%52.2% | 7.3r21—867% | |
| Retained earnings | −103—−482% | −102—−603% | −98—−542% | −92—−429% | −80—−263% | −72—−346% | −61—−312% | −48—−221% | −32—−116% | −11r−225—−1288% | |
| Shareholders' equity | — | — | 14−11.5%79.7% | 16−33.6%75.8% | 25+73.8%80.7% | 14+7.0%68.2% | 13+116%67.7% | 6.1−53.0%28.3% | 13—47.8% | −6.5r−19—−767% | |
| Minority interests | — | — | — | 0.1+62.5%0.3% | 0.0+48.1%0.1% | 0.0—0.1% | — | — | — | — | |
| Total equity | 15+20.4%68.3% | 12−16.2%71.2% | 14−11.8%79.7% | 16−33.5%76.1% | 25+73.7%80.8% | 14+7.2%68.4% | 13+116%67.7% | 6.1—28.3% | — | — | |
| Total liabilities and equity | 21+25.4%100% | 17−6.1%100% | 18−15.8%100% | 22−29.4%100% | 30+47.0%100% | 21+6.2%100% | 20−9.7%100% | 22−20.7%100% | 27+3138%100% | 0.8r1.3—100% | |
| Shares outstanding | 1.8+19.2%— | 1.5+5.2%— | 1.4+24.5%— | 1.1r23−95.0%— | 23+29.2%— | 18+123%— | 7.9+244%— | 2.3r34−77.5%— | 10+2170%— | 0.4r26—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.2+3.8%2.3% | 1.2−2.1%2.9% | 1.2+0.5%4.2% | 1.2+7.8%6.0% | 1.1+3.5%6.4% | 1.1−2.2%6.9% | 1.1−11.6%13.7% | 1.3+70.3%25.8% | 0.7+563%25.7% | 0.1r0.3—6.5% | |
| Share-based compensation | 1.2−18.9%2.3% | 1.5−4.3%3.6% | 1.6−59.0%5.3% | 3.8+102%18.7% | 1.9+167%10.6% | 0.7+5.2%4.4% | 0.7+26.3%8.2% | 0.5+980%10.8% | 0.0+308%1.7% | 0.0r0.1—0.7% | |
| Cash from operating activities | 0.7+56.0%1.3% | 0.4—1.1% | −3.6—−12.1% | −7.7—−38.1% | −6.6—−37.2% | −7.4—−46.8% | −9.1—−112% | −6.8—−138% | −6.7—−231% | −1.0r−3.6—−55.7% | |
| Capital expenditure | −0.3—−0.6% | −0.2—−0.5% | −0.1—−0.4% | −0.3—−1.4% | −0.7—−3.9% | −0.2—−1.0% | −0.1—−0.7% | −0.1—−2.0% | −0.1—−4.9% | −0.0—−1.1% | |
| Cash from investing activities | −0.3—−0.6% | −0.2—−0.5% | −0.1—−0.4% | −0.3—−1.4% | −0.7—−3.9% | −0.1—−0.6% | −0.1—−0.7% | −0.1—−2.0% | −0.0−104%−1.5% | 1.0—58.4% | |
| Debt issued | — | 0.3—0.6% | — | — | — | 0.8—5.0% | — | 0.3−4.8%6.1% | 0.3−40.0%10.9% | 0.5—30.5% | |
| Shares issued | — | 0.1−96.5%0.2% | 2.2+1640%7.6% | 0.1−99.2%0.6% | 16+81.5%91.7% | 8.9+34.7%56.2% | 6.6+230%81.1% | 2.0—41.0% | — | 0.5—27.6% | |
| Cash from financing activities | 0.9—1.7% | −0.3−119%−0.8% | 1.7—5.9% | −0.2−101%−1.1% | 16+74.2%92.0% | 9.3−3.4%58.8% | 9.7+41.9%118% | 6.8−4.1%139% | 7.1+816%245% | 0.8r2.2—45.0% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | — | — | 0—0.0% | |
| Change in cash | 1.3—2.4% | −0.1—−0.3% | −1.9—−6.6% | −8.2−191%−40.5% | 9.0+398%51.0% | 1.8+287%11.4% | 0.5—5.7% | −0.0−111%−0.8% | 0.4—12.8% | −0.2r−0.3—−10.7% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 54+22.5%100% | 16+8.2%100% | 15+21.9%100% | 15+43.3%100% | 6.7*+22.9%100% | 15+27.6%100% | 12+21.9%100% | 11+38.5%100% | 5.5*+25.9%100% | 12—100% | 10—100% | 7.7—100% | 4.3*—100% | |
| Cost of revenue | 15+22.3%28.8% | 4.0+5.1%24.1% | 3.9+20.5%25.8% | 4.0+42.9%25.9% | 3.6*+27.2%53.2% | 3.8+28.3%24.8% | 3.2+18.3%26.1% | 2.8+11.0%26.0% | 2.8*+21.1%51.4% | 2.9—24.7% | 2.7—26.9% | 2.5—32.5% | 2.3*—53.5% | |
| Gross profit | 12+21.0%23.1% | 3.4+12.4%20.6% | 3.1+29.1%20.9% | 2.7+27.3%17.7% | 3.1*+18.4%46.8% | 3.0+32.0%19.8% | 2.4+41.6%19.7% | 2.1+133%20.0% | 2.6*+31.4%48.6% | 2.3—19.1% | 1.7—17.0% | 0.9—11.9% | 2.0*—46.5% | |
| Operating expenses | 14+12.6%25.9% | 3.4+10.1%20.6% | 3.7+14.8%24.8% | 4.2+38.5%27.0% | 2.6*−13.1%38.7% | 3.1+6.7%20.2% | 3.3+11.2%26.4% | 3.0+0.2%28.0% | 3.0*+4.0%54.7% | 2.9—24.2% | 2.9—28.9% | 3.0—38.7% | 2.9*—66.2% | |
| Operating income | −1.5—−2.8% | 0.0—0.0% | −0.6—−4.0% | −1.4—−9.3% | 0.5*—8.1% | −0.1—−0.4% | −0.8—−6.7% | −0.9—−8.0% | −0.3*—−6.2% | −0.6—−5.0% | −1.2—−11.9% | −2.1—−26.8% | −0.9*—−19.7% | |
| Other non-operating income (expense) | — | −0.0—−0.1% | 0.4−57.7%2.5% | — | −0.0*—−0.2% | −0.0—−0.1% | 0.9—7.3% | — | −0.0*—−0.5% | −0.0—−0.2% | −0.0—−0.1% | — | — | |
| Income before tax | −1.1—−2.1% | −0.0—−0.0% | −0.2−396%−1.5% | −1.4—−9.4% | 0.5*—7.9% | −0.1—−0.5% | 0.1—0.6% | −0.9—−8.2% | −0.4*−139%−6.7% | −0.6—−5.3% | −1.2—−12.1% | −2.1—−26.9% | 0.9*—21.4% | |
| Net income including minority interests | −1.1—−2.1% | −0.0—−0.0% | −0.2−396%−1.5% | −1.4—−9.4% | 0.5*—7.9% | −0.1—−0.5% | 0.1—0.6% | −0.9—−8.2% | −0.4*−139%−6.7% | −0.6—−5.3% | −1.2—−12.1% | −2.1—−26.9% | 0.9*—21.4% | |
| Net income attributable to shareholders | −1.1—−2.1% | −0.0—−0.0% | −0.2−396%−1.5% | −1.4—−9.4% | 0.5*—7.9% | −0.1—−0.5% | 0.1—0.6% | −0.9—−8.2% | — | — | — | — | — | |
| Earnings per share, basic | — | — | -0.12−340%— | -0.81—— | — | -0.05—— | 0.05—— | -0.59—— | — | -0.42—— | -0.83—— | -1.46—— | — | |
| Earnings per share, diluted | — | — | -0.12−340%— | -0.81—— | — | -0.05—— | 0.05—— | -0.59—— | — | -0.42—— | -0.83—— | -1.46—— | — | |
| Shares, weighted average (basic) | 1.8+9.4%— | 1.8+9.4%— | 1.8+18.0%— | 1.8+18.7%— | — | 1.6+10.6%— | 1.5+3.5%— | 1.5+5.5%— | — | 1.5—— | 1.5—— | 1.4r1.4—— | — | |
| Shares, weighted average (diluted) | 1.8+9.4%— | 1.8+9.4%— | 1.8+11.5%— | 1.8+18.7%— | — | 1.6+10.6%— | 1.6+9.5%— | 1.5+5.5%— | — | 1.5—— | 1.5—— | 1.4r1.4—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 3.6—16.5% | 3.6+55.1%16.5% | 3.1+172%14.4% | 2.6+156%12.5% | 2.7+90.9%12.4% | 2.3+119%10.9% | 1.1−11.6%6.0% | 1.0+31.1%5.7% | 1.4−7.5%8.2% | 1.1—6.2% | 1.3—7.4% | 0.8—4.7% | 1.5—8.3% | |
| Receivables | 2.0—9.4% | 2.0+4.6%9.4% | 2.3+53.2%10.7% | 2.0+104%9.6% | 2.0+148%9.3% | 2.0+91.7%9.3% | 1.5+34.4%7.9% | 1.0+7.7%5.5% | 0.8−38.6%4.7% | 1.0—6.0% | 1.1—6.4% | 0.9—5.4% | 1.3—7.2% | |
| Inventory | 0.9—4.2% | 0.9+15.6%4.2% | 0.8−26.7%3.6% | 0.9+5.5%4.2% | 0.9+29.1%4.4% | 0.8+33.6%3.7% | 1.1+62.2%5.6% | 0.8+55.1%4.6% | 0.7+88.5%4.3% | 0.6—3.5% | 0.7—3.8% | 0.5—3.2% | 0.4—2.1% | |
| Other current assets | 0.5—2.4% | 0.5−17.0%2.4% | 0.4+8.2%1.9% | 0.5+2.2%2.3% | 0.5−13.0%2.2% | 0.6+4.6%2.9% | 0.4+15.7%2.0% | 0.5+20.7%2.6% | 0.5+8.9%3.2% | 0.6—3.5% | 0.3—1.9% | 0.4—2.3% | 0.5—2.7% | |
| Current assets | 7.0—32.5% | 7.0+24.3%32.5% | 6.5+61.3%30.7% | 5.9+81.0%28.5% | 6.0+75.0%28.3% | 5.7+74.1%26.8% | 4.1+20.5%21.5% | 3.3+26.3%18.4% | 3.5−6.3%20.3% | 3.3—19.2% | 3.4—19.4% | 2.6—15.6% | 3.7—20.3% | |
| Property, plant and equipment | 1.1—5.2% | 1.1+46.4%5.2% | 1.1+42.5%5.1% | 0.7−4.7%3.5% | 0.7+1.4%3.4% | 0.8+2.4%3.6% | 0.8+10.7%4.0% | 0.8+14.7%4.3% | 0.7−2.7%4.2% | 0.8—4.4% | 0.7—3.9% | 0.7—4.0% | 0.7—4.1% | |
| Right-of-use (leased) assets | 2.4—11.3% | 2.4+0.7%11.3% | 2.3+32.9%10.9% | 2.5+55.8%11.8% | 2.6+549%12.0% | 2.4+444%11.5% | 1.8+253%9.3% | 1.6+183%8.8% | 0.4−35.5%2.3% | 0.4—2.6% | 0.5—2.9% | 0.6—3.3% | 0.6—3.4% | |
| Other intangible assets | 10—47.0% | 10−8.5%47.0% | 10−8.3%49.0% | 11−8.2%51.3% | 11−8.0%51.2% | 11−7.8%52.7% | 11−7.7%60.6% | 12−7.6%65.4% | 12−7.4%69.8% | 12—71.4% | 12—71.3% | 13—75.7% | 13—70.8% | |
| Total assets | 22—100% | 22+2.7%100% | 21+13.3%100% | 21+17.0%100% | 21+25.4%100% | 21+24.8%100% | 19+8.6%100% | 18+7.0%100% | 17−6.1%100% | 17—100% | 17—100% | 17—100% | 18—100% | |
| Accounts payable | 1.2—5.7% | 1.2+9.2%5.7% | 1.0−16.5%4.6% | 1.4+50.4%6.6% | 1.1+83.0%5.3% | 1.1+62.3%5.4% | 1.2+36.1%6.2% | 0.9+0.1%5.1% | 0.6−0.6%3.6% | 0.7—4.1% | 0.9—4.9% | 0.9—5.4% | 0.6—3.4% | |
| Debt due within a year | 0.1—0.5% | 0.1+280%0.5% | 0.1+152%0.3% | 0.0−79.6%0.1% | 0.0−89.9%0.1% | 0.0−93.2%0.1% | 0.0−88.4%0.2% | 0.1+10.5%0.8% | 0.3+26.4%1.7% | 0.4—2.6% | 0.2—1.4% | 0.1—0.8% | 0.2—1.3% | |
| Current liabilities | 4.0—18.4% | 4.0−10.5%18.4% | 3.7−15.0%17.4% | 3.8−12.0%18.3% | 3.8−12.2%17.6% | 4.5−0.6%21.1% | 4.4−5.3%23.1% | 4.3+30.2%24.4% | 4.3+36.0%25.1% | 4.5—26.4% | 4.6—26.5% | 3.3—20.0% | 3.1—17.4% | |
| Long-term debt | 0.2—1.1% | 0.2+324%1.1% | 0.3+306%1.2% | 0.0−42.9%0.2% | 0.0−39.0%0.2% | 0.1−34.5%0.3% | 0.1−32.6%0.3% | 0.1−29.3%0.4% | 0.1−27.4%0.5% | 0.1—0.5% | 0.1—0.5% | 0.1—0.6% | 0.1—0.6% | |
| Lease liabilities (non-current) | 2.0—9.4% | 2.0−3.1%9.4% | 2.0+27.0%9.2% | 2.1+52.2%10.0% | 2.2+971%10.3% | 2.1+726%9.9% | 1.5+413%8.2% | 1.4+288%7.7% | 0.2−49.4%1.2% | 0.3—1.5% | 0.3—1.7% | 0.4—2.1% | 0.4—2.2% | |
| Total liabilities | 6.8—31.5% | 6.8−7.5%31.5% | 6.6+0.5%30.8% | 6.6+9.0%31.9% | 6.8+37.8%31.7% | 7.4+47.9%35.0% | 6.5+25.5%34.7% | 6.1+58.1%34.2% | 4.9+33.5%28.8% | 5.0—29.5% | 5.2—30.0% | 3.9—23.2% | 3.7—20.3% | |
| Retained earnings | −104—−481% | −104—−481% | −104—−490% | −104—−501% | −103—−482% | −103—−488% | −103—−549% | −103—−581% | −102—−603% | −102—−602% | −101—−586% | −100—−603% | −98—−542% | |
| Shareholders' equity | — | — | — | — | — | — | — | — | — | — | — | — | 14—79.7% | |
| Total equity | 15—68.5% | 15+8.1%68.5% | 15+20.1%69.2% | 14+21.1%68.1% | 15+20.4%68.3% | 14+15.1%65.0% | 12+1.4%65.3% | 12−8.4%65.8% | 12−16.2%71.2% | 12—70.5% | 12—70.0% | 13—76.8% | 14—79.7% | |
| Total liabilities and equity | 22—100% | 22+2.7%100% | 21+13.3%100% | 21+17.0%100% | 21+25.4%100% | 21+24.8%100% | 19+8.6%100% | 18+7.0%100% | 17−6.1%100% | 17—100% | 17—100% | 17—100% | 18—100% | |
| Shares outstanding | 1.8—— | 1.8+2.7%— | 1.8+18.0%— | 1.8+18.6%— | 1.8+19.2%— | 1.7+17.8%— | 1.5+3.2%— | 1.5+5.2%— | 1.5+5.2%— | 1.5—— | 1.5—— | 1.4—— | 1.4—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.2−3.7%2.2% | 0.3*+1.6%1.9% | 0.3*−5.2%1.9% | 0.3−13.3%1.8% | 0.3*+2.7%4.6% | 0.3*+2.7%2.0% | 0.3*+3.4%2.5% | 0.3+6.6%3.0% | 0.3*+1.7%5.5% | 0.3*—2.5% | 0.3*—2.9% | 0.3—3.9% | 0.3*—6.8% | |
| Share-based compensation | 2.0+36.8%3.7% | 0.1−50.0%0.6% | 0.8+100%5.3% | 1.0+135%6.5% | 0.1*−76.0%1.6% | 0.2−50.0%1.3% | 0.4+33.3%3.2% | 0.4+18.5%3.9% | 0.4*+12.1%8.0% | 0.4—3.4% | 0.3—3.0% | 0.4—4.6% | 0.4*—9.0% | |
| Cash from operating activities | 1.7+92.3%3.2% | 0.6*+6000%3.7% | 0.7*+87.0%4.4% | 0.1—0.4% | 0.4*−35.2%5.5% | 0.0*−75.6%0.1% | 0.4*−29.4%2.9% | −0.0—−0.4% | 0.6*+396%10.4% | 0.0*—0.3% | 0.5*—4.9% | −0.7—−8.6% | 0.1*—2.6% | |
| Capital expenditure | −0.3—−0.6% | −0.1*—−0.3% | −0.1*—−0.9% | −0.1—−0.3% | −0.1*—−1.1% | −0.1*—−0.4% | −0.1*—−0.5% | −0.1—−1.3% | −0.0*—−0.8% | −0.1*—−0.9% | — | — | −0.0*—−1.1% | |
| Cash from investing activities | −0.3—−0.6% | −0.1*—−0.3% | −0.1*—−0.9% | −0.1—−0.3% | −0.1*—−1.1% | −0.1*—−0.4% | −0.1*—−0.5% | −0.1—−1.3% | −0.0*—−0.8% | −0.1*—−0.9% | — | — | −0.0*—−1.1% | |
| Debt issued | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | — | |
| Shares issued | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0.0*—0.1% | 0.1—0.9% | 0*—0.0% | |
| Shares bought back | — | 0*—0.0% | — | — | — | — | — | — | — | — | — | — | — | |
| Cash from financing activities | −0.1−117%−0.2% | −0.1*−104%−0.3% | −0.1*—−0.4% | −0.1—−0.4% | 0.1*—0.8% | 1.2*—8.0% | −0.2*−348%−1.5% | −0.2—−1.8% | −0.2*—−3.4% | −0.2*—−1.3% | 0.1*—0.7% | −0.1—−0.8% | −0.1*—−2.9% | |
| Change in cash | 1.3+1.5%2.4% | 0.5*−57.4%3.1% | 0.5*+317%3.1% | −0.0—−0.3% | 0.3*+3.0%5.2% | 1.2*—7.7% | 0.1*−77.5%0.9% | −0.4—−3.5% | 0.3*—6.2% | −0.2*—−1.9% | 0.5*—5.0% | −0.7—−9.4% | −0.1*—−1.4% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Precipio, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Service revenue, net$51 M95%+30%
- Product revenue(total)$3 M5.1%+5.0%
Business segments
- Single reportable segment$24 M45%+30%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Precipio, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Ilan S. Danieli | $473 K | $784 K | $310 K | $208 |
| 2024Ilan S. Danieli | $462 K | $422 K | $401 K | $50 |
| 2023Ilan S. Danieli | $473 K | $314 K | $275 K | $59 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Precipio, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 3 · Material agreement 1 · Agreement ended 2 · New debt 1 · Shareholder vote 3 · Results announced 4
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Agreement ended | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementNew debt | 8-K | |
| Agreement ended | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2017 | $8 M | Private placement after listing | $2 to $10 million | 3 | equity | SEC |
| Apr 2017 | $1 M | Private placement after listing | Under $2 million | 5 | debt, options | SEC |
| Jan 2016 | $2 M | Private placement after listing | $2 to $10 million | 5 | equity, options | SEC |
| Jul 2015 | $3 M | Private placement after listing | $2 to $10 million | 2 | equity, options | SEC |
| Dec 2014 | $2 M | Private placement after listing | Under $2 million | 8 | debt, options | SEC |
| Oct 2014 | $2 M | Private placement after listing | $2 to $10 million | 9 | equity, options | SEC |
| Mar 2014 | $7 M | Private placement after listing | $2 to $10 million | 3 | equity | SEC |
| Jan 2013 | $8 M | Private placement after listing | $2 to $10 million | 32 | equity, options | SEC |
| Feb 2012 | $22 M | Private placement after listing | $10 to $50 million | 56 | equity, options | SEC |
| Dec 2011 | $3 M | No. 1 | $2 to $10 million | 3 | debt, options | SEC |
| Dec 2010 | $6 M | Issued in a merger or acquisition | $2 to $10 million | 3 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2007 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2005 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Precipio, Inc. compares in Diagnostics and Research
- Market cap$38 M · higher than 19% of 110
- Revenue$53 M · higher than 28% of 123
- Net margin-1.8% · higher than 41% of 112
- Revenue growth28.0% · higher than 85% of 89
- Price / sales0.6× · lower than 92% of 85
- Price / book2.6× · lower than 53% of 84
- FCF yield0.9% · higher than 57% of 66
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Precipio, Inc.🇺🇸 | $38 M | — | -1.8% | +28.0% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 22, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Precipio, Inc.? Verify and update this profile — free
Show Precipio, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.